
Dr. Amy Paller discusses how targeting IL-4 and IL-13 can improve burden of AD.

This video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia features Dr. Lisa Weibel presenting how local type 2 inflammation within the skin contributes to epidermal barrier dysfunction, dysbiosis, and neuroimmune dysfunction, leading to the clinical signs and symptoms of AD. Dr. Weibel also reviews how systemic inflammation affects organ systems beyond the skin, and could potentially manifest as atopic and non-atopic comorbidities.

In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Lisa Weibel discusses how type 2 inflammation contributes to epidermal barrier dysfunction and AD signs and symptoms.

In this highlight video from the May 2024 ADVENT symposium at ESPD’s Annual Meeting in Košice, Slovakia, Dr. Lisa Weibel presents how type 2 inflammation contributes to dysbiosis, skin infections, and itch in patients with AD.

Prof. Mullol discusses the contribution of nasal obstruction and inflammation in loss of smell in patients with CRSwNP

Prof. Mullol share his opinion on connection between loss of smell and sleep disorder in patients with CRSwNP.

Prof. Mullol highlights the utility of visual analog scale for quick assessment of sense of smell in patients with CRSwNP.

Dr. Klaus Rabe, MD, PhD, discusses the key inflammatory processes in patients with COPD and their implications for patient care.

Dr. Casale discusses the critical role of barrier disruption in atopic dermatitis

In this video clip from the EAACI 2024 symposium, Dr. Mullol discusses the challenge of defining active nasal disease using an endoscope.

Dr. Backer discusses assessing remission in CRSwNP by evaluating the patient's sense of smell in this video clip from the EAACI 2024 symposium.

Watch this short video to learn how type 2 inflammation, skin barrier dysfunction, and neurosensitization contribute to chronic itch and the itch-scratch cycle in atopic dermatitis